Avricore Health Achieves Milestones and Outlines UK Expansion Roadmap for HealthTab Platform

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) announces HealthTab has now screened more than 3,500 patients in community pharmacies across North East and North Central London. During an initial one-month pilot of HbA1c testing for diabetes screening, the Company completed 2,295 HbA1c tests across 57 locations, achieving a monthly per-location average 10 times higher than previously achieved in Canada.

Expansion Roadmap

The Company has published “The Path Forward,” a strategic update outlining the Company’s UK expansion strategy for its HealthTab point-of-care testing platform. The presentation is now available on the Company’s website at avricore.com/investor-kit.

The update outlines Avricore’s progression from NHS-linked pilot programmes in London toward broader regional and national expansion across England, supported by clinical outcomes, independent evaluation, and growing institutional support.

UK Programme Milestones

HealthTab has gained meaningful traction within the NHS, including the screening of more than 3,500 patients in community pharmacies across North East and North Central London through a collaboration with Barts Health NHS Trust. In an initial lipid-screening cohort of 556 patients, approximately one in five was identified as having elevated cardiovascular risk.

The programme has been independently evaluated by UCLPartners and has received attention from NHS England’s Chief Pharmaceutical Officer, as well as coverage by BBC National News. In addition, the British Heart Foundation, awarded a $385,000 grant to Barts Health, supporting an Inclisiran secondary-prevention pilot within the pharmacy network featuring HealthTab.

Expanding Test Menu and Revenue Model

HealthTab is continuing to expand its test menu within the NHS network. HbA1c testing for diabetes screening launched in Q1 2026, and UACR kidney function testing is planned for Q3 2026. In the first month of HbA1c availability, the network completed 2,295 tests in total across 57 pilot locations, approaching the ~3,000 tests per month average previously achieved across more than 700 locations in Canada.

The Company expects current pilots to expand to more than 100 pharmacy sites in Q2 2026, with monthly subscription revenue expected to begin in the second half of 2026.

The Path Forward presentation also outlines a phased growth roadmap targeting 500 or more active UK locations by mid-2027, within a longer-term addressable market of more than 10,000 community pharmacies across 42 NHS England integrated care boards. The Company currently has 700 analyzers staged and available for deployment from its London office.

Schreibe Deinen Kommentar